{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Previously Marketed
Source:
Diluted Hydrobromic Acid U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Diluted Hydrobromic Acid U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Hydrobromic acid is a useful reagent for generating organobromine compounds. It was shown that hydrobromic acid could initiate or exacerbate inflammatory pulmonary disease.
Status:
US Previously Marketed
Source:
Solution of Potassium Arsenite U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Solution of Potassium Arsenite U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Arsenite ion is a form of inorganic trivalent arsenic. It is derived from arsenous acid and known mainly for forming the basis of Fowler's solution (1% potassium arsenite (KAsO2). Fowler's solution has had a fascinating history in medicine during the past 200 years. The use of Fowler's solution was first described and published as a treatment for malaria and syphilis in the late 1700s. Many clinical applications for Fowler's solutions have been studied and utilized over the years, but toxicities have limited its utility. Even so, arsenic trioxide, chemically related to Fowler's solution, was approved by the US Food and Drug Administration for treating acute promyelocytic leukemia. The chronic arsenic exposure is a cause of immense health distress as it accounts for the increased risk of various disorders such as cardiovascular abnormalities, diabetes mellitus, neurotoxicity, and nephrotoxicity. In addition, the exposure to arsenic has been suggested to affect the liver function and to induce hepatotoxicity. Moreover, few studies demonstrated the induction of carcinogenicity especially cancer of the skin, bladder, and lungs after the chronic exposure to arsenic.
Status:
US Previously Marketed
Source:
Sodium Hypophosphite U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Sodium Hypophosphite U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Hypophosphite is a strong reducing agent, that has been used in the 1850s as a remedy for pulmonary tuberculosis. Hypophosphites were used extensively in pharmaceutical preparations, elixirs, and tonics. Hypophosphite does not appear to have adverse toxicological effects, and the sodium, calcium, and potassium salts are considered GRAS. Hypophosphite use in foods may not be limited to one function. Hypophosphites have been used in foods as antioxidants, stabilizers, meat pickling accelerator, and vegetable protein flow inducer.
Status:
US Previously Marketed
Source:
Pyrogallol U.S.P.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Previously Marketed
First marketed in 1921
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
US Previously Marketed
Source:
Potassium Arsenate
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Potassium arsenate is a chemical compound of potassium and arsenic. It is derived from arsenic acid. Arsenic is a chemical element that has the symbol As and atomic number 33. It is a poisonous metalloid that has many allotropic forms: yellow (molecular non-metallic) and several black and grey forms (metalloids) are a few that are seen. Three metalloidal forms of arsenic with different crystal structures are found free in nature (the minerals arsenopyrite and the much rarer arsenolamprite and pararsenolamprite), but it is more commonly found as a compound with other elements. Potassium arsenate is used in the textile, tanning and paper industries, and as an insecticide, especially for fly paper. In medicine arsenic was the preferred treatment for syphilis for many years. It was also thought to treat malaria, leukemia, and chorea. One type of arsenic preparation that became a popular type of patent medicine of the late 1800’s on into the early 1900s’ was Fowler’s solution, which was sold as a treatment for syphilis as well as a general tonic. Fowler’s solution was not a brand of patent medicine but rather a formula containing 1% potassium arsenate, proposed by Thomas Fowler in 1786. Potassium arsenate is toxic and carcinogenic to humans.
Status:
US Previously Marketed
Source:
Bismuth Betanaphthol U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Bismuth Betanaphthol U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Previously Marketed
Source:
Potassium Permanganate U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Potassium Permanganate U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Sodium permanganate is the inorganic compound used as oxidant and etchant in printed circuitry. Sodium permanganate is a purplish-colored, inorganic salt compound, which is primarily available in aqueous form as a monohydrate. It is miscible in water, ether, ethanol, and liquid chlorine. Sodium permanganate offers a high concentration of permanganate ions. Owing to high solubility in water, it is used for etching of plastic parts, as etching requires a high concentration of permanganate ions. Sodium permanganate is also used for water treatment and soil treatment, as it is capable of degrading phenols, BTEX, chlorinated ethenes, and PAHS and removing hydrogen sulfide.
Status:
US Previously Marketed
Source:
Potassium Hypophosphite U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Potassium Hypophosphite U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Previously Marketed
First marketed in 1921
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Mephobarbital us a barbiturate derivative used primary as an anticonvulsant, but also as a sedative and anxiolytic. Marketing of mephobarbital was discontinued in 2012.